News
March 3, 2023
Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
November 5, 2022
CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities
September 10, 2022
While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease progression by more than 2.5 times
May 3, 2022
Patent registration in South Korea opens door to commercial agreements in an enormous market with high economic potential for CureLab
April 22, 2022
The university is also renewing its agreement with CureLab Oncology to support its phase II clinical trials
March 30, 2022
As the terrible Ukraine-Russia situation evolves, what does this portend for scientists located in the region? Scientists from countries with differing political systems have long collaborated with colleagues located in politically distressed and war-torn regions. Despite the associated challenges, these collaborations have combined their respective strengths and even leveraged the unique characteristics of their regional differences.
January 31, 2022
Partnership aims to accelerate CureLab’s clinical studies by providing access to intellectual and scientific resources that can advance research and discovery in ovarian cancer prevention and treatment strategies
November 23, 2021
Patent registration in India opens door to commercial agreements in an enormous market with rising incidence of cancer
November 11, 2021
Along with the OncologyTube host Stephanie Comello, Dr. Alex Shneider and Prof. Sergei Krasny discuss results from our clinical studies underway in Belarus. If you have 30 minutes, we invite you to watch the video. We’ve condensed the highlights below.
September 16, 2021
The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
January 20, 2020
CureLab Oncology CEO Alex Shneider’s lament is a biopharma industry that exhibits little appetite for those discoveries made while coloring outside the lines
April 29, 2020
CureLab Oncology’s Dr. Alex Shneider Publishes Paper: Can Melatonin Reduce the Severity of COVID-19?
Melatonin may prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients’ health after the active phase of the infection is over
August 11, 2021
Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
September 16, 2021
The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy